| 摘要 |
PCT No. PCT/GB91/01337 Sec. 371 Date Feb. 3, 1993 Sec. 102(e) Date Feb. 3, 1993 PCT Filed Aug. 5, 1991 PCT Pub. No. WO92/02520 PCT Pub. Date Feb. 20, 1992.Compounds of the formula: <IMAGE> or tautomeric forms and a pharmaceutically acceptable salt, and pharmaceutically acceptable solvates thereof, wherein: A1 is a substituted or unsubstituted oxazole substituted by up to 4 substituents selected from the group consisting of C1-6-alkyl, C1-6-alkoxy, phenyl, and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a benzene ring, and wherein the carbon atoms of the benzene ring represented by the said two substituents are unsubstituted or substituted with up to three groups selected from halogen, C1-6-alkyl, phenyl, C1-6-alkoxy, halo-C1-6-alkyl, hydroxy, amino, nitro, carboxy, C1-6-alkoxycarbonyl, C1-6-alkoxycarbonyl-C1-6-alkyl, C1-6-alkylcarbonyloxy, and C1-5-alkylcarbonyl; Rl is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkylcarbonyloxy group, a phenyl-C1-6-alkyl group, wherein the phenyl moiety may be substituted or unsubstituted, or a substituted or unsubstituted phenyl group, wherein the said phenyl groups may be substituted with up to three groups selected from halogen, C1-6-alkyl, phenyl, C1-6-alkoxy, halo-C1-6-alkyl, hydroxy, amino, nitro, carboxy, C1-6-alkoxycarbonyl, C1-6-alkoxycarbonyl-C1-6-alkyl, C1-6-alkylcarbonyloxy, and C1-6-alkylcarbonyl; A2 is a benzene ring having in total up to five substituents wherein three optional substituents are selected from halogen, C1-6-alkyl, phenyl, C1-6-alkoxy, halo-C1-6-alkyl, hydroxy, amino, nitro, carboxy, C1-6-alkoxycarbonyl. C1-6-alkoxycarbonyl-C1-6-alkyl, C1-6-alkylcarbonyloxy, and C1-6-alkylcarbonyl; and n is an integer from 2 to 6, are disclosed as hypoglycemics, hypolipidemics and antihypertensives.
|
